Targeting those specific mutations, such as BCR-ABL in chronic myelocytic leukemia and PML-RAR-alpha in acute promyelocytic leukemia (APL), has certainly provided clinical benefits and validated the basic principles of a genetic origin of cancer. This evidence concerns the gene ABL1 and acute promyelocytic leukemia.